![](https://monteverdelaw.com/wp-content/uploads/case-logo/immunomedics-inc.jpg)
Immunomedics, Inc. (IMMU) related to its sale to Gilead Sciences, Inc. Under the terms of the agreement, Immunomedics shareholders will receive $88.00 per share for each share of Immunomedics stock owned.
Immunomedics, Inc. (IMMU) related to its sale to Gilead Sciences, Inc. Under the terms of the agreement, Immunomedics shareholders will receive $88.00 per share for each share of Immunomedics stock owned.